Alle Storys
Folgen
Keine Story von SYGNIS AG mehr verpassen.

SYGNIS AG

EANS-News: SYGNIS Pharma AG
SYGNIS´ reduction of share capital in a 3:1 ratio was entered in the commercial register

Heidelberg (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Capital measures
SYGNIS´ reduction of share capital in a 3:1
ratio was entered in the commercial register
Heidelberg,  15  December  2010  -  SYGNIS  Pharma  AG  (Frankfurt:  
LIO;   ISIN DE0005043509; Prime Standard) today announced the 
registration  of  the  capital reduction in the commercial register 
on the  basis  of  the  resolution  of  the Annual General Meeting 
held on 30 November 2010. Hereby  the  share  capital  is reduced 
from EUR 41,258,643  to  EUR  13,752,881,  allocated  to  13,752,881 
shares outstanding.
At the same time the implementation  of  the  capital  reduction  on 
the  stock exchange and the consolidation of the shares in a 3:1 
ratio were  initiated.  It is expected that the consolidation of the 
shares will be completed  by  the  end of December 2010. Due to this 
process the trading of the SYGNIS  shares  on  the stock exchange 
will be temporarily suspended.
The purpose of this capital reduction is  primarily  to  improve  the
Company´s abilities  to  interact  on  the  capital  markets  and  to
open  up  financing alternatives, since the Company´s share price has
been below the  nominal  value of EUR 1 for a long period. It is 
anticipated that this move will better support the development of the
shares.
About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg,  
is  a  specialty  pharmaceutical company listed on the Prime Standard
of the German stock exchange.  The  Company is focused on the 
research and  development  of  innovative  therapies  for  the 
treatment of disorders of the Central Nervous System. SYGNIS´ core 
projects  are currently Acute Stroke for which SYGNIS´ lead clinical 
programme  is  AX200  as well as the preclinical KIBRA-project for 
the treatment of  different  forms  of dementia. All these disorders 
are  characterized  by  the  fact  that,  as  the disease progresses,
nerve cells are damaged and die.  Although  there  is  great medical 
demand, there are currently no  or  only  inadequate  treatment  
options available. SYGNIS´ strategy for growth includes the 
development of new  products from its own research and through 
in-licensing and acquisitions.
For further information please contact:
SYGNIS Pharma AG:
Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812 
franz-werner.haas@sygnis.de
Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187
### Disclaimer Some statements included in this  press  release,  
relating  neither  to  proven financial results nor other  historical
data,  should  be  viewed  as  forward- looking, i.e. not definite. 
Such statements are  mainly  predictions  of  future results, trends,
plans or goals. These statements should not  be  considered  to be 
total guarantees since given their very nature they are subject to 
known  and unknown risks and imponderability and can be affected  by 
other  factors  as  a consequence of which the actual results, plans 
and goals  of  SYGNIS  Pharma  AG may deviate greatly from the  
established  conclusions  or  implied  predictions contained in such 
statements. SYGNIS does not undertake to  publicly  update  or revise
these statements in the light of new information  or  future  results
or for any other reason.  ###
end of announcement                               euro adhoc

Further inquiry note:

Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Weitere Storys: SYGNIS AG
Weitere Storys: SYGNIS AG
  • 11.11.2010 – 08:51

    EANS-News: SYGNIS announces six month results of fiscal year 2010/2011

    Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. 6-month report Heidelberg (euro adhoc) - SYGNIS announces six month results of fiscal year 2010/2011 Heidelberg, 11 November 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today published its ...

  • 29.10.2010 – 09:42

    EANS-Adhoc: SYGNIS Pharma AG announces strategic restructuring

    ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Company Information 29.10.2010 Ad-hoc SYGNIS Pharma AG announces strategic restructuring Heidelberg, 29 October 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) announced today a ...

  • 28.10.2010 – 20:07

    EANS-Adhoc: Dr. Alfred Bach resigns as CEO of SYGNIS Pharma AG

    ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. C.E.O. Interviews 28.10.2010 Ad-hoc Dr. Alfred Bach resigns as CEO of SYGNIS Pharma AG Heidelberg, 28 October 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) announced today that the ...